Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-01-06 Regulatory Filings
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Cla
Regulatory Filings Classification · 95% confidence The document is a press release from Oculis announcing positive topline results from a Phase 2 clinical trial (ACUITY). It details the primary safety endpoints and secondary efficacy endpoints of the trial. This type of announcement, which provides initial highlights of clinical trial results, is classified as an Earnings Release (ER) or, more broadly in the context of biopharma, a clinical trial results announcement which falls under the Earnings Release/Clinical Update category in this schema.
2025-01-06 English
Oculis Announces Positive OCS-05 Ph..
Earnings Release Classification · 95% confidence The document is a press release dated January 6, 2025, announcing positive topline results from the Phase 2 ACUITY trial for the drug OCS-05 for Acute Optic Neuritis. It details safety and efficacy endpoints (retinal structure and visual function improvements), includes quotes from management and key opinion leaders, and announces an upcoming investor/analyst call. This structure—announcing clinical trial results and providing context/next steps—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a detailed announcement of clinical trial results, it is most closely aligned with an Earnings Release (ER) which often includes key operational and clinical milestones, or potentially an Investor Presentation (IP) if it were structured as slides, but the format here is a formal press release announcing results. Given the focus on clinical trial results and the announcement of a call to discuss them, ER is the most appropriate fit among the options, as it serves as the primary communication of recent performance/milestones outside of a formal quarterly/annual report. It is not a full transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA). Q1 2025
2025-01-06 Icelandic
Oculis Announces Positive OCS-05 Ph..
Earnings Release Classification · 98% confidence The document is a press release dated January 6, 2025, announcing positive topline results from the Phase 2 ACUITY trial for the drug OCS-05 in acute optic neuritis. It details safety and efficacy endpoints, includes quotes from management and medical experts, and announces a subsequent investor webcast. This structure—announcing key clinical trial results and financial/operational updates outside of a formal periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate news. Since the content is focused on clinical trial results and future development plans, and it explicitly mentions an upcoming analyst call to review the results, it fits best under the 'Earnings Release' category, which often encompasses major operational/clinical milestones announced via press release, especially when followed by a call. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a specific regulatory filing like DIRS or DIV. It is an announcement of results, not just an announcement that a report is attached (RPA). Therefore, ER is the most appropriate classification. Q1 2025
2025-01-06 English
Notification of Major Changes in Voting Rights - Brunnur.pdf
Major Shareholding Notification Classification · 100% confidence The document is a standard 'flöggun' (flagging) notification, which is the Icelandic term for a major shareholding notification. It explicitly references 'lög nr. 20/2021 um upplýsingaskyldu útgefenda verðbréfa og flöggunarskyldu' (Act on disclosure requirements for issuers of securities and flagging obligations). It details the change in shareholding percentage (dropping below 5%) for 'Brunnur vaxtarsjóður slhf.' in 'Oculis Holding AG'. This fits the definition of a Major Shareholding Notification (MRQ).
2025-01-04 Icelandic
Oculis Publishes Notification of Major Changes in Voting Rights
Major Shareholding Notification Classification · 95% confidence The document is a short announcement (626 characters) stating that a 'Notification of Major Changes in Voting Rights' is attached. It serves as a notification of a filing rather than the detailed regulatory filing itself. According to the 'Menu vs Meal' rule, announcements of reports or filings are classified as Report Publication Announcements (RPA).
2025-01-04 English
Oculis Publishes Notification of Ma..
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Eyðublað vegna breytinga á verulegum hlut atkvæðisréttar (flöggun)" which translates to 'Form regarding changes in significant voting rights (flagging)'. It explicitly references Icelandic law regarding disclosure obligations and flagging requirements for securities issuers (lög nr. 20/2021). The content details changes in the number of shares and voting rights held by an entity ('Brunnur vaxtarsjóður slhf.') in another company ('Oculis Holding AG'), specifically noting a transaction date (Jan 3, 2025) and a threshold crossing ('Undir 5%'). This structure and content strongly indicate a notification of a change in major shareholding or insider transaction related to voting rights. Comparing this to the provided definitions, 'Major Shareholding Notification' (MRQ) is the most appropriate fit, as it covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. It is not a Director's Dealing (DIRS) as the entity is a fund, nor is it a general regulatory filing (RNS) because MRQ is more specific.
2025-01-03 Icelandic

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.